Evidence map›Paper›PMID 40097242›Full record

ArticleNeuropsychopharmacology reports2025

Unwanted Clinical Complications Following the Consumption of Death Coffee: A Case Series.

Amir-Hassan Bordbari, Mahkameh Soltani, Yousef Ashoori, Fatemeh Moslemi Najarcolaii, Zakaria Zakariaei

Abstract readCase Reports
In one paragraph

Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amir-Hassan BordbariStudent Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Mahkameh SoltaniDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Yousef AshooriDepartment of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Fatemeh Moslemi NajarcolaiiDepartment of Forensic Medicine and Toxicology, Mazandaran Registry Center for Opioids Poisoning, Antimicrobial Resistance Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Zakaria ZakariaeiDepartment of Forensic Medicine and Toxicology, Mazandaran Registry Center for Opioids Poisoning, Antimicrobial Resistance Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0003-4835-9349

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

"Death Coffee" is an incredibly potent brew with caffeine content three times higher than conventional coffees, making it the strongest coffee in the world. Caffeine, a relatively safe psychostimulant substance consumed as dietary products or daily drinks, enhances physical and mental performance. According to long-lasting safe experiences of daily coffee consumption, caffeine intoxication with a cup of coffee is hardly believable in Iran. This paper reports five cases of coffee toxicity with a single cup of coffee within the last weeks. Presentation of toxicity varied among patients and ranged from lethargy to hallucination, tremors, agitation, shortness of breath, and decreased level of consciousness. Surprisingly, all five patients consumed an unknown caffeinated beverage called Death Coffee within 12 weeks, demonstrating that a new and unknown beverage prevails in our region.

Indexed as

CaffeineCentral Nervous System StimulantsCoffeeAdultFemaleHumansIranMaleMiddle AgedCaffeineCentral Nervous System StimulantsCoffeecaffeinedeath coffeehallucinationintoxicationsingle cup

Identifiers

PMID40097242
PMCPMC11913531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.